Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider John Fesko sold 291 shares of the company's stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $206.16, for a total value of $59,992.56. Following the completion of the sale, the insider owned 187,220 shares of the company's stock, valued at $38,597,275.20. This represents a 0.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
John Fesko also recently made the following trade(s):
- On Monday, April 27th, John Fesko sold 1,688 shares of Natera stock. The shares were sold at an average price of $204.10, for a total value of $344,520.80.
- On Tuesday, March 10th, John Fesko sold 707 shares of Natera stock. The shares were sold at an average price of $204.13, for a total value of $144,319.91.
Natera Price Performance
Natera stock opened at $206.77 on Wednesday. The company's 50 day simple moving average is $201.91 and its 200 day simple moving average is $214.51. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $256.36. The firm has a market capitalization of $29.42 billion, a price-to-earnings ratio of -135.14 and a beta of 1.57.
Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.81. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. The business had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. During the same quarter last year, the firm earned ($0.41) EPS. As a group, analysts predict that Natera, Inc. will post -1.71 EPS for the current fiscal year.
More Natera News
Here are the key news stories impacting Natera this week:
- Neutral Sentiment: CEO Steven Leonard Chapman sold 902 shares (≈$185,956) under a pre-arranged Rule 10b5-1 plan to cover taxes on vested awards. This reduced his ownership by ~0.60%. SEC Form 4
- Neutral Sentiment: Insider John Fesko sold 291 shares (≈$59,993) under a Rule 10b5-1 plan to cover tax withholding, a ~0.16% reduction in his stake. SEC Form 4
- Neutral Sentiment: Insider Solomon Moshkevich sold 3,405 shares (≈$693,564) under a pre-arranged plan to cover taxes, reducing his holding by ~2.34%. SEC Form 4
- Neutral Sentiment: CFO Michael Burkes Brophy executed two 10b5-1 sales (482 shares at ~$210.49 and 313 shares at ~$206.16) totaling ~795 shares (~$165,984) to cover tax withholdings, trimming his stake by under 1%. SEC Form 4
Analyst Upgrades and Downgrades
Several research analysts recently weighed in on NTRA shares. William Blair started coverage on shares of Natera in a research note on Tuesday, April 14th. They set an "outperform" rating on the stock. Wall Street Zen raised shares of Natera from a "hold" rating to a "buy" rating in a research note on Saturday, April 18th. Weiss Ratings reissued a "sell (d-)" rating on shares of Natera in a research note on Tuesday, April 21st. Morgan Stanley lowered their target price on Natera from $265.00 to $250.00 and set an "overweight" rating for the company in a research note on Tuesday, March 3rd. Finally, Canaccord Genuity Group reissued a "buy" rating on shares of Natera in a research note on Monday, January 12th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $253.47.
Get Our Latest Analysis on Natera
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the business. Robinhood Asset Management LLC bought a new stake in Natera during the fourth quarter worth $12,981,000. JPMorgan Chase & Co. raised its position in Natera by 9.4% during the third quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company's stock worth $1,871,914,000 after acquiring an additional 1,003,129 shares in the last quarter. Rakuten Investment Management Inc. bought a new stake in Natera during the third quarter worth $34,096,000. New York State Common Retirement Fund raised its position in Natera by 63.2% during the third quarter. New York State Common Retirement Fund now owns 148,247 shares of the medical research company's stock worth $23,863,000 after acquiring an additional 57,400 shares in the last quarter. Finally, Krilogy Financial LLC bought a new stake in Natera during the third quarter worth $1,323,000. Institutional investors and hedge funds own 99.90% of the company's stock.
Natera Company Profile
(
Get Free Report)
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
